Caicun Zhou

7.9k total citations · 3 hit papers
136 papers, 3.5k citations indexed

About

Caicun Zhou is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Caicun Zhou has authored 136 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 87 papers in Pulmonary and Respiratory Medicine, 78 papers in Oncology and 46 papers in Molecular Biology. Recurrent topics in Caicun Zhou's work include Lung Cancer Treatments and Mutations (78 papers), Cancer Immunotherapy and Biomarkers (28 papers) and Cancer Genomics and Diagnostics (24 papers). Caicun Zhou is often cited by papers focused on Lung Cancer Treatments and Mutations (78 papers), Cancer Immunotherapy and Biomarkers (28 papers) and Cancer Genomics and Diagnostics (24 papers). Caicun Zhou collaborates with scholars based in China, United States and Germany. Caicun Zhou's co-authors include Shengxiang Ren, Xuefei Li, Chunxia Su, Tao Jiang, Chao Zhao, Guanghui Gao, Gerald Schmid‐Bindert, Xiaoxia Chen, Songwen Zhou and Xiaoxia Chen and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Caicun Zhou

131 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

2015 367 citations Tony Mok, Yi‐Long Wu et al. Clinical Cancer Research profile →
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer

2021 196 citations Caicun Zhou, Sang‐We Kim et al. profile →
Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial

2023 126 citations Enriqueta Felip, Nasser K. Altorki et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Caicun Zhou

Since Specialization

Citations

This map shows the geographic impact of Caicun Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caicun Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caicun Zhou more than expected).

Fields of papers citing papers by Caicun Zhou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Caicun Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caicun Zhou. The network helps show where Caicun Zhou may publish in the future.

Co-authorship network of co-authors of Caicun Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Caicun Zhou. A scholar is included among the top collaborators of Caicun Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Caicun Zhou. Caicun Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Taletrectinib in ROS1 + Non–Small Cell Lung Cancer: TRUST 2025 ·Journal of Clinical Oncology ·M. Pérol, Wei Li, Nathan A. Pennell, Geoffrey Liu, Yuichiro Ohe, Filippo de Braud, Misako Nagasaka, Enriqueta Felip, Anwen Xiong, Yongchang Zhang, Huijie Fan, Xicheng Wang, Shuanglian Li, Rose Lai, (unknown), Xianyu Zhang, Wenfeng Chen, Lyudmila Bazhenova, Caicun Zhou	10
2	Reply to: “Baseline Brain Metastasis Imbalance in TRUST: Implications for Interpreting Intracranial Efficacy of Taletrectinib” and “Taletrectinib in ROS1 Fusion–Positive Non–Small Cell Lung Cancer: Promising Yet Premature?” 2025 ·Journal of Clinical Oncology ·M. Pérol, Wei Li, Rose Lai, Caicun Zhou	1
3	Intracranial outcomes of 1L selpercatinib in advanced RET fusion-positive NSCLC: LIBRETTO-431 study. 2024 ·Journal of Clinical Oncology ·M. Pérol, Kōichi Goto, Benjamin Solomon, Keunchil Park, Ernest Nadal, Emilio Bria, (unknown), Jair Bar, (unknown), Tarun Puri, Li J, (unknown), Boris K. Lin, Caicun Zhou	0
4	FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004) 2024 ·Lung Cancer ·Alexander I. Spira, Byoung Chul Cho, Enriqueta Felip, Edward B. Garon, Kōichi Goto, Melissa Johnson, Natasha B. Leighl, Antonio Passaro, David Planchard, Sanjay Popat, James Chih‐Hsin Yang, Xiaoqian Lu, Yong Jiang, (unknown), (unknown), Marcin Kowanetz, Shirley Wang, John T. Le, Jerry Y. Hsu, Caicun Zhou	2
5	CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non–Small Cell Lung Cancer 2024 ·Journal of Clinical Oncology ·M. Pérol, Benjamin Solomon, Kōichi Goto, Keunchil Park, Ernest Nadal, Emilio Bria, Claudio Martín, Jair Bar, (unknown), Tarun Puri, Li J, Minji K. Uh, Boris K. Lin, Caicun Zhou	5
6	CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer 2024 ·Signal Transduction and Targeted Therapy ·Haowei Wang, Anwen Xiong, Xiaoxia Chen, Junhong Guo, Zhuoran Tang, Chunyan Wu, (unknown), Caicun Zhou, Jian Chen, (unknown), Tao Jiang	4
7	Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study 2024 ·JTO Clinical and Research Reports ·Caicun Zhou, You Lu, Sang‐We Kim, Thanyanan Reungwetwattana, (unknown), Yiping Zhang, Jianxing He, Jin‐Ji Yang, Ying Cheng, Se‐Hoon Lee, Jianhua Chang, Jian Fang, (unknown), Lilian Bu, (unknown), Tingting Xu, V.R. Archer, Magalie Hilton, (unknown), Li Zhang	2
8	PL02.04 Phase 3 Study of Ivonescimab (AK112) vs. Pembrolizumab as First-line Treatment for PD-L1-positive Advanced NSCLC: Primary Analysis of HARMONi-2 2024 ·Journal of Thoracic Oncology ·Caicun Zhou, Jingbo Chen, (unknown), Long Wang, Biying Liu, Jiayi Yao, Huanzi Zhong, Jiarui Li, (unknown), Yun Sun, Heng Ge, Qin Shi, Min Zhou, Zhiyu Han, Jingyuan Wang, Qing Bu, Yong Zhao, Jin‐Ji Yang, (unknown)	15
9	P2.14-07 Updated Results of Camrelizumab Plus Nab-Paclitaxel and Carboplatin as First-Line Treatment for ES-SCLC: A Phase II Trial 2023 ·Journal of Thoracic Oncology ·Shengxiang Ren, Jia Yu, Ai‐Sheng Xiong, Qi Wang, Lei Wang, Bin Chen, Meng‐Hang Yang, Wěi Li, Jin Yuan, Chao Zhao, Caicun Zhou	0
10	Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial breakdown → 2023 ·Annals of Oncology ·Enriqueta Felip, Nasser K. Altorki, Caicun Zhou, Eric Vallières, Alex Martínez‐Martí, Achim Rittmeyer, Antonio Chella, Martin Reck, (unknown), Meijuan Huang, (unknown), Virginia McNally, Minu K. Srivastava, Elizabeth Bennett, (unknown), (unknown)	126
11	Personalized circulating tumor DNA detection to monitor immunotherapy efficacy and predict outcome in locally advanced or metastatic non‐small cell lung cancer 2023 ·Cancer Medicine ·Lei Cheng, Guanghui Gao, Chao Zhao, Haowei Wang, Chao Yao, (unknown), (unknown), Feng Li, (unknown), (unknown), Xiaoxia Chen, Xuefei Li, Caicun Zhou	4
12	Comparison of the somatic genomic landscape between central- and peripheral-type non-small cell lung cancer 2023 ·Lung Cancer ·Lei Wang, (unknown), Zheng Zhang, Minlin Jiang, Shifu Chen, Deping Zhao, (unknown), Caicun Zhou	1
13	Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study 2022 ·Therapeutic Advances in Medical Oncology ·Fei Zhou, Haoyue Guo, Xiaolong Zhou, Huikang Xie, Tian Tian, Wencheng Zhao, Guanghui Gao, Anwen Xiong, Lei Wang, Wěi Li, Xiaoxia Chen, Yan Zhang, Jue Fan, Fengying Wu, Yongchang Zhang, Caicun Zhou	10
14	Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice 2019 ·Lung Cancer ·Yijun Jia, Sha Zhao, Tao Jiang, Xuefei Li, Chao Zhao, Yiwei Liu, Ruoshuang Han, Meng Qiao, (unknown), Chunxia Su, Shengxiang Ren, Caicun Zhou	23
15	PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs 2018 ·Cancer Biology and Medicine ·(unknown), Xiaoxia Chen, (unknown), Jun Qian, Tao Jiang, Caicun Zhou, Maciej Ciebiada	25
16	MA15.03 The Predictive Value of Mutation/Neoantigen Burden from ctDNA on the Efficacy of PD-1 Blockade in Advanced NSCLC 2017 ·Journal of Thoracic Oncology ·Weijing Cai, Caicun Zhou, Chunxia Su, Feng Wu, Shengxiang Ren, Xiaoxia Chen, Fred R. Hirsch	2
17	Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy breakdown → 2015 ·Clinical Cancer Research ·Tony Mok, Yi‐Long Wu, Jin Soo Lee, Chong‐Jen Yu, Virote Sriuranpong, Jennifer Sandoval-Tan, Guia Ladrera, Sumitra Thongprasert, Vichien Srimuninnimit, Meilin Liao, Yunzhong Zhu, Caicun Zhou, Fatima Fuerte, Benjamin Margono, Wei Wen, Julie Tsai, Matt Truman, Barbara Klughammer, David S. Shames, Lin Wu	367
18	Gefitinib-Resistance Is Related to BIM Expression in Non-Small Cell Lung Cancer Cell Lines 2012 ·Cancer Biotherapy and Radiopharmaceuticals ·Heyan Li, Songwen Zhou, Xuefei Li, Daoyuan Wang, Yongsheng Wang, Caicun Zhou, Gerald Schmid‐Bindert	24
19	The association between polymorphisms in the DNA nucleotide excision repair genes and RRM1 gene and lung cancer risk 2012 ·Thoracic Cancer ·Xuefei Li, Jie Zhang, Chunxia Su, Xinping Zhao, Liang Tang, Caicun Zhou	6
20	Selection and establishment of gefitinib-resistant PC9 cell line and its gene expression profile 2008 ·Tumori ·Caicun Zhou	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact